RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Regulatory Update

Regulatory Update

Posted 01 June 2010

In an effort to improve discussion and flow of information, the US Food and Drug Administration (FDA) recently announced it has changed the way its expert panels review and discuss information during public hearings on devices under review for premarket approval. In the past, panel discussions have not always reflected a panel's final vote on approvability. The changes address staffing issues, voting procedures and other items related to information presentation and flow of discussion. For example, instead of voting on the approvability of premarket applications, including conditions of approval, the panel will now vote on the safety and effectiveness of a device and its risk versus its benefit. Further, instead of a unified, consensus analysis of supporting data, reviewers will present the range of scientific opinion in the group. This change was put in effect 1 May 2010.

 

© 2022 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe